CA2089162A1 - Onset of antiestrogen resistance in breast cancer - Google Patents

Onset of antiestrogen resistance in breast cancer

Info

Publication number
CA2089162A1
CA2089162A1 CA002089162A CA2089162A CA2089162A1 CA 2089162 A1 CA2089162 A1 CA 2089162A1 CA 002089162 A CA002089162 A CA 002089162A CA 2089162 A CA2089162 A CA 2089162A CA 2089162 A1 CA2089162 A1 CA 2089162A1
Authority
CA
Canada
Prior art keywords
tamoxifen
treatment
trans
cis
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002089162A
Other languages
English (en)
French (fr)
Inventor
C. Kent Osborne
Michael W. Degregorio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2089162A1 publication Critical patent/CA2089162A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002089162A 1990-09-05 1991-09-04 Onset of antiestrogen resistance in breast cancer Abandoned CA2089162A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US577,790 1990-09-05
US07/577,790 US5119827A (en) 1990-09-05 1990-09-05 Mechanisms of antiestrogen resistance in breast cancer

Publications (1)

Publication Number Publication Date
CA2089162A1 true CA2089162A1 (en) 1992-03-06

Family

ID=24310178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002089162A Abandoned CA2089162A1 (en) 1990-09-05 1991-09-04 Onset of antiestrogen resistance in breast cancer

Country Status (4)

Country Link
US (2) US5119827A (forum.php)
EP (1) EP0547141A1 (forum.php)
CA (1) CA2089162A1 (forum.php)
WO (1) WO1992003973A1 (forum.php)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5704045A (en) * 1995-01-09 1997-12-30 King; Douglas L. System and method of risk transfer and risk diversification including means to assure with assurance of timely payment and segregation of the interests of capital
US5742775A (en) * 1995-01-18 1998-04-21 King; Douglas L. Method and apparatus of creating financial instrument and administering an adjustable rate loan system
DE19628298C2 (de) * 1996-07-12 2002-04-11 Max Delbrueck Centrum Verfahren zum Nachweis einer Hormon- bzw. Antihormonresistenz bei Tumoren
AU9071098A (en) * 1997-07-29 1999-02-22 Lambert C. J. Dorssers Breast cancer resistance genes, methods for their detection and uses thereof
HUP0002852A3 (en) 1997-08-15 2001-11-28 Univ Durham A method of preventing or treating estrogen-dependent diseases and disorders using triphenil-ethylene derivatives
AU3105700A (en) * 1998-12-08 2000-06-26 Board Of Regents, The University Of Texas System Methods for detection of antiestrogen-resistant breast cancer
US20040018527A1 (en) * 2002-05-17 2004-01-29 Chang Jenny C. Differential patterns of gene expression that predict for docetaxel chemosensitivity and chemo resistance
RU2232391C2 (ru) * 2002-09-05 2004-07-10 ООО "Медицинская диагностика" Способ дифференциальной диагностики злокачественных новообразований и соматических незлокачественных заболеваний
US20050152835A1 (en) * 2003-10-31 2005-07-14 Pak Koon Y. Technetium-99M glucarate methods of use for monitoring tissues
US7829291B2 (en) * 2005-02-17 2010-11-09 Vanderbilt University In situ analysis of tissues
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP3143392B1 (en) * 2014-05-12 2023-02-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen metabolites by mass spectrometry
WO2018045208A1 (en) * 2016-09-02 2018-03-08 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
EP4357784A3 (en) 2016-09-02 2024-07-31 Board of Regents, The University of Texas System Collection probe and methods for the use thereof
JP2021504703A (ja) 2017-11-27 2021-02-15 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 低侵襲性収集プローブおよびその使用方法
BR112021014553A2 (pt) 2019-01-25 2021-10-05 Board Of Regents, The University Of Texas System Aparelho e métodos para limpeza e/ou troca de dispositivos médicos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
US5030417A (en) * 1984-09-19 1991-07-09 Mayo Foundation For Medical Education And Research Method and kit to assay for steroid receptor functionality in cancerous cells
US4806464A (en) * 1984-09-19 1989-02-21 Mayo Foundation For Medical Education And Research Nuclear binding assay for steroid receptor functionality in cancerous cells
EP0272791A3 (en) * 1986-11-17 1989-06-28 Oncotech Method to monitor and circumvent acquired resistance to chemotherapy in humans
WO1989001153A1 (en) * 1987-07-24 1989-02-09 Xoma Corporation Methods for breast cancer detection
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer

Also Published As

Publication number Publication date
EP0547141A1 (en) 1993-06-23
WO1992003973A1 (en) 1992-03-19
US5384260A (en) 1995-01-24
US5119827A (en) 1992-06-09
EP0547141A4 (forum.php) 1994-01-05

Similar Documents

Publication Publication Date Title
US5384260A (en) Detection of onset of antiestrogen resistance in breast cancer
Wiebe et al. Identification of estrogenic tamoxifen metabolite (s) in tamoxifen-resistant human breast tumors.
Onn et al. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis
Richardson et al. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography–tandem electrospray ionization mass spectrometry
Lien et al. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile
Durrett et al. A sensitive radioenzymatic assay for catechol drugs
Muir Flax lignansanalytical methods and how they influence our understanding of biological activity
Mauvais-Jarvis et al. trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast
Markaverich et al. Leukotoxin diols from ground corncob bedding disrupt estrous cyclicity in rats and stimulate MCF-7 breast cancer cell proliferation
Murphy et al. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM)
Evans et al. Analysis of cocaine and cocaine metabolites by high pressure liquid chromatography
Levine et al. Distribution of venlafaxine in three postmortem cases
US20170176446A1 (en) Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer
Hatano et al. D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2
Verhagen et al. Metabolism of a [18F] fluorine labeled progestin (21-[18F] fluoro-16α-ethyl-19-norprogesterone) in humans: a clue for future investigations
WO2002012445A1 (en) Detection of cox-2 activity and anandamide metabolites
JPH06509221A (ja) 治療に対する腫瘍反応の予測方法
Murphy et al. Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatoraphy-mass spectrometry (GC-MS) using selected ion monitoring (SIM)
Mihailescu et al. Identification of tamoxifen and metabolites in human male urine by GC/MS
Bowman et al. Hypothalamic, pituitary and uterine cytoplasmic and nuclear oestrogen receptors and their relationship to the serum concentration of tamoxifen and its metabolite, 4-hydroxytamoxifen, in the ovariectomized rat
Wolf et al. Estrogen and progestin receptors in human prostatic carcinoma
L’homme et al. Time-resolved fluoroimmunoassay of plasma and urine O-desmethylangolensin
Boros et al. Isofenphos induced metabolic changes in K562 myeloid blast cells
Fuhrman et al. Soy intake is associated with increased 2-hydroxylation and decreased 16α-hydroxylation of estrogens in Asian-American women
Muskiet et al. Determination of some L-3, 4-dihydroxyphenylalanine and dopamine metabolites in urine by means of mass fragmentography.

Legal Events

Date Code Title Description
FZDE Discontinued